论文部分内容阅读
亚硒酸钠用于预防克山病和治疗大骨节病在我国已应用多年。然而,有关合理安全有效的给药方案尚不很清楚。为此,本文继单次口服亚硒酸钠药代动力学研究之后,探讨了多次口服亚硒酸钠的稳态血药浓度。用荧光分光光度法测定了给药前及给药后不同时间的全血硒水平。测得达90%以上平均稳态浓度为0.112±0.047μg/ml,达稳态时间区间为34—106小时,大多数个体在4～5个半衰期达稳态。与单次口服测得的半衰期相符。
Sodium selenite for the prevention of Keshan disease and treatment of Kashin-Beck disease has been applied in our country for many years. However, the rationale for safe and effective dosing regimens is not yet known. To this end, following a single oral sodium selenite pharmacokinetic study, the steady-state plasma concentration of oral sodium selenite was explored several times. Whole blood selenium levels were measured before and after administration by fluorescence spectrophotometry. Measured up to 90% of the average steady-state concentration of 0.112 ± 0.047μg / ml, up to the steady-state time interval of 34-106 hours, most individuals in the 4 to 5 half-life steady state. Consistent with the single oral measured half-life.